<?xml version='1.0' encoding='utf-8'?>
<document id="30214893"><sentence text="Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV/HCV coinfection." /><sentence text="The objective of the study was to evaluate the role of a clinical pharmacist in hepatitis C virus (HCV) treatment of patients living with HIV/HCV coinfection" /><sentence text="" /><sentence text="We conducted a descriptive study to quantify the functions of a clinical pharmacist in HCV treatment of patients living with HIV/HCV coinfection who were initiating HCV treatment at a publicly funded clinic between March 18, 2015 and September 15, 2016" /><sentence text=" The clinical pharmacist's role was categorized into eight categories: 1) HCV prior authorization (PA) completion; 2) HCV medication adherence counseling; 3) HCV drug-drug interaction (DDI) counseling and screening; 4) HCV medication counseling regarding common adverse events (AEs); 5) HCV counseling regarding HCV treatment outcomes and risk of reinfection; 6) ordering laboratory tests and interpretation of HCV laboratory values; 7) HIV medication AE assessment; and 8) other (including refilling medications and management of other comorbidities)" /><sentence text="" /><sentence text="One hundred and thirty-five patients initiated treatment during this timeframe: 77" /><sentence text="0% were males, 56" /><sentence text="3% non-cirrhotic, 77" /><sentence text="0% HCV treatment-naÃ¯ve, 45" /><sentence text="9% HCV genotype 1a, and 83" /><sentence text="0% initiated on ledipasvir/sofosbuvir"><entity charOffset="16-26" id="DDI-PubMed.30214893.s12.e0" text="ledipasvir" /><entity charOffset="27-37" id="DDI-PubMed.30214893.s12.e1" text="sofosbuvir" /><pair ddi="false" e1="DDI-PubMed.30214893.s12.e0" e2="DDI-PubMed.30214893.s12.e0" /><pair ddi="false" e1="DDI-PubMed.30214893.s12.e0" e2="DDI-PubMed.30214893.s12.e1" /></sentence><sentence text=" The clinical pharmacist completed 150 PAs, counseled on HCV medication adherence in 79" /><sentence text="2% of patients, conducted HCV DDI counseling and screening in 54" /><sentence text="2%, and monitored HCV medication AEs in 54" /><sentence text="2%" /><sentence text=" The clinical pharmacist counseled patients on HCV treatment outcomes and risk of reinfection in 53" /><sentence text="1%, ordered laboratory tests in 44" /><sentence text="8%, and reported and interpreted laboratory values in 44" /><sentence text="8%" /><sentence text=" The clinical pharmacist assessed HIV medication AEs in 54" /><sentence text="2% of patients and participated in other activities in 42" /><sentence text="7%" /><sentence text="" /><sentence text="A clinical pharmacist's expertise as part of a multidisciplinary care team facilitates optimal treatment outcomes and provides critical support in the management of DAA therapy in individuals living with HIV/HCV coinfection" /><sentence text="" /></document>